Ocrelizumab/Hyaluronidase-ocsq

N/A

Report date: 2024/09/14 09:42:03

Base Information

Drug NameOcrelizumab/Hyaluronidase-ocsq

Drug Alias NameOCREVUS ZUNOVO

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionCD20-directed cytolytic effectsAnti-CD20Hyaluronic acid modulators

TargetsB-lymphocyte antigen CD20Hyaluronic acid

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsMultiple Sclerosis

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date2024/09/13

Country/TerritoryUnited States

CombinationsYes Ocrelizumab

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A